Division of Hematology With Stem Cell Transplantation, Hemostaseology and Medical Oncology, Department of Internal Medicine I, Ordensklinikum Linz, Fadingerstrasse 1, 4020 Linz and Seilerstätte 4, 4010, Linz, Austria.
Doctoral Programme MedUni Vienna, Medical University of Vienna, Spitalgasse 23, 1090, Vienna, Austria.
J Cancer Res Clin Oncol. 2023 Aug;149(10):7113-7123. doi: 10.1007/s00432-023-04671-9. Epub 2023 Mar 6.
Polypharmacy is a significant problem in patients with incurable cancer and a method to optimize pharmacotherapy in this patient group is lacking. Therefore, a drug optimization tool was developed and tested in a pilot test.
A multidisciplinary team of health professionals developed a "Tool to Optimize Pharmacotherapy in Patients with Incurable Cancer" (TOP-PIC) for patients with a limited life expectancy. The tool consists of five sequential steps to optimize medications, including medication history, screening for medication appropriateness and drug interactions, a benefit-risk assessment using the TOP-PIC Disease-based list, and shared decision-making with the patient. For pilot testing of the tool, 8 patient cases with polypharmacy were analyzed by 11 oncologists before and after training with the TOP-PIC tool.
TOP-PIC was considered helpful by all oncologists during the pilot test. The median additional time required to administer the tool was 2 min per patient (P < 0.001). For 17.4% of all medications, different decisions were made by using TOP-PIC. Among possible treatment decisions (discontinuation, reduction, increase, replacement, or addition of a drug), discontinuation of medications was the most common. Without TOP-PIC, physicians were uncertain in 9.3% of medication changes, compared with only 4.8% after using TOP-PIC (P = 0.001). The TOP-PIC Disease-based list was considered helpful by 94.5% of oncologists.
TOP-PIC provides a detailed, disease-based benefit-risk assessment with recommendations specific for cancer patients with limited life expectancy. Based on the results of the pilot study, the tool seems practicable for day-to-day clinical decision-making and provides evidence-based facts to optimize pharmacotherapy.
多种药物治疗是绝症患者面临的一个重大问题,而目前缺乏针对该患者群体优化药物治疗的方法。因此,开发了一种药物优化工具,并在试点研究中进行了测试。
一个多学科的医疗保健专业人员团队为预期寿命有限的绝症患者开发了一种“优化绝症患者药物治疗工具”(TOP-PIC)。该工具包括优化药物治疗的五个连续步骤,包括用药史、药物适宜性和药物相互作用筛查、使用 TOP-PIC 疾病基础清单进行获益-风险评估,以及与患者共同决策。在工具的试点测试中,在接受 TOP-PIC 工具培训前后,11 名肿瘤学家分析了 8 例多种药物治疗的患者病例。
所有肿瘤学家都认为在试点测试期间该工具很有帮助。每位患者使用该工具所需的额外时间中位数为 2 分钟(P<0.001)。使用 TOP-PIC 做出了不同的决策,涉及所有药物的 17.4%。在可能的治疗决策(停药、减少剂量、增加剂量、替换药物或添加药物)中,最常见的是停药。如果不使用 TOP-PIC,医生对 9.3%的药物变化不确定,而使用 TOP-PIC 后仅为 4.8%(P=0.001)。94.5%的肿瘤学家认为 TOP-PIC 疾病基础清单很有帮助。
TOP-PIC 提供了详细的、基于疾病的获益-风险评估,并为预期寿命有限的癌症患者提供了具体的建议。基于试点研究的结果,该工具似乎适用于日常临床决策,并为优化药物治疗提供了基于证据的事实。